Moderna Inc (LTS:0A45)
$ 39.3575 -1.0175 (-2.51%) Market Cap: 15.50 Bil Enterprise Value: 9.98 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 58/100

Moderna Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 12:30AM GMT
Cory William Kasimov
JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone. My name is Cory Kasimov. I'm the senior large-cap biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, Moderna. Here to present for Moderna is the CEO, Stéphane Bancel, and please note that following Stéphane's presentation, there's a breakout just across the hall in the Georgian room. So with that, Stéphane?

StÃ;phane Bancel
Moderna, Inc. - CEO & Director

© -

Thank you, Cory. Good afternoon, everybody. Thank you for joining us. Before starting, let me remind you, we'll be making forward-looking statements and there are risks associated with investing in Moderna, which you can find on the SEC website or on our website.

So let me start by capping a little bit 2019. The key highlights before looking at the future, what's coming. So today Moderna has 20 program in development. So of course, I'm not going to go through all of these. You can find the slides on our website. But

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot